key: cord-0798191-4jh07zov
authors: Shah, Unmil; Rahulan, Vijil; Srinivas, R.; Kumar, Sharanya; Anoop Mohandas, K.; Kori, Santosh; Panda, Sushant; Singh, Vivek; Kumar, Pradeep; Prasanna, G.; Satish Rao, I.; Kalle, Abhiram; Manish, D.; John, Prem Anand; Mahesh, B. N.; Dutta, Prabhat; Attawar, Sandeep
title: Clinico-radiological-pathological profile and outcomes of Lung transplantation in post covid-19 phenotype: A single centre experience
date: 2022-04-11
journal: Transplant Proc
DOI: 10.1016/j.transproceed.2022.03.007
sha: 726a7111c634889b76f98687de91df0812043f30
doc_id: 798191
cord_uid: 4jh07zov

Background Lung Transplantation (LTx) has come as hope for select patients with post COVID ARDS. It's a different phenotype with unique challenges. We aimed to bring out our experience and outcomes of LTx for post-COVID ARDS. Methods The study is retrospective case series from single centre from India. All the post COVID End stage Lung Disease who underwent Bilateral LTx between 1st May 2020 and 30th August 2021 were included. LTx was performed following no improvement with optimal medical management with adequate time provided for recovery. Information relating to demographics, co-morbidities, pre-transplantation status, peri-operative parameters, gross and histopathological findings of explanted lungs , post transplantation morbidity and mortality were analysed. Results The study included 23 patients. The median age of patients in this study was 42 years and 20 (87%) participants were men. The mean duration of ICU stay was 15.83 ± 6.61 days. Mortality was observed among 8 (34.78%) participants. Mean survival time was 34.54 weeks. Among 8 patients who expired, the cause of death was sepsis for 6 patients (75.0%), neurological CVA for 1 patient (12.5%) and CMV for 1 patient (12.5%). All the deaths were reported in PGD grade 2 & 3 category. No rejections were observed on 1st and 3rd month surveillance biopsies. Conclusion LTx is the definitive option for survival in select patients with severe post- COVID-19-associated End Stage Lung Disease. Above study brings out various challenges involved in such phenotype and also interesting observations in post-operative recovery.

As per WHO, till Jan 2022 , India has witnessed confirmed 326,279,424 COVID -19 cases and 5,536,609 cases had mortality. Worldwide, there have been 226,844,344 confirmed cases of COVID-19, including 4,666,334 deaths 1 . Current evidence suggests ARDS is the most common pulmonary complication of the COVID-19 2 . Various mechanisms of lung injury in COVID-19 have been described, with both viral and immune-mediated mechanisms being implicated 3 .

A smaller percentage of patients with more severe disease require ventilatory support and are admitted to high dependency and intensive care units (ICUs). In a Chinese study of 1099 hospitalised COVID-19 patients, the primary composite end point being admission to an intensive care unit (ICU), the use of mechanical ventilation, or death, the primary composite end point occurred in 67 patients (6.1%). including 5.0% who were admitted to the ICU, 2.3% who underwent invasive mechanical ventilation, and 1.4% who died. Extracorporeal membrane oxygenation was performed in 5 patients (0.5%) with severe disease 4 . The mortality associated with COVID-19 is considerable-in a large UK study by Vlachos et al, 18% of them were admitted to the ICU, 52% met criteria for ICU outreach team activation, and 61% had treatment limitations placed during their admission. Hospital mortality was 26% and ICU mortality was 34% 5 , concluding that COVID-19 is associated with a high burden of mortality for patients treated in the ward and the ICU hospital mortality was independently associated with increasing age, male sex, history of chronic kidney disease, increasing baseline C-reactive protein level, and dyspnoea at presentation. In review by Peter George et al, COVID-19-related ICU mortality has been reported to be between 16% and 78% 6 . Lung transplantation has been offered as a lifesaving therapy for select patients with COVID-19 who have persistent respiratory failure despite several weeks or months of support in the ICU. Most patients who progress to severe respiratory failure do have comorbidities that may be a challenge in deciding transplant candidacy. Many will develop secondary complications such as renal dysfunction, muscle wasting, or other organ failure while on ECMO as mentioned by Cypel and Keshavjee 7 . LTx can be considered as a salvage therapy for carefully selected patients who have severe treatment-refractory ARDS as described by Lang et al. 8 So far most of the published studies are based on anectodotal case reports and small sample size case series. To understand the outcomes and factors associated with the outcomes is challenging due to such small sample size. Experience of other centres with higher volumes of data may throw light on these aspects, if not providing scientifically robust inferences. These studies may establish a strong platform and provide meaningful insights for further large scale and scientifically robust studies.

Here we report a retrospective study, a single centre experience of 23 Lung Transplantations done in recipients with Post-Covid fibrotic progressive End Stage Lung Disease (ESLD) . We also describe challenges faced pre-operatively as well as post-operatively for such recipients. This is presumably first case series from a single centre in India describing lung transplant experience in such phenotype with reasonable outcomes.

Patients received treatment according to the local standard of care from a multidisciplinary COVID-19 care team . Referral to the lung transplantation team was made when at least 4 weeks had elapsed since the onset of Respiratory Failure and there was no evidence of lung recovery as agreed by the multidisciplinary team as per criteria elaborated by Toronto group 7 .

Not all patients with severe COVID-19 who were treated at the respective centres were referred to lung transplantation after 4 weeks. Common reasons that precluded lung transplantation evaluation included multiorgan failure (MOF), inability to assess neurological status if the patient was unresponsive or not awake, complications such as sepsis or stroke, and general contraindications relevant to lung transplantation. Each patient was then evaluated by the lung transplantation team with standard evaluation protocol and considered a candidate for transplantation if other programmatic criteria were met, according to the International Society for Heart and Lung Transplantation (ISHLT) guidelines. Patients with MOF were excluded from lung trans-plantation evaluation for COVID-19. All patients underwent extensive Pulmonary Rehabilitation for optimisation while on waitlist. All recipients were operated with conventional Clamshell incision. All recipients were transplanted on converting VV to VA ECMO intraoperatively. Intraoperatively, all patients received Induction Immunosuppression with Inj Basiliximab( 20 mg ) along with Inj Methylprednisolone 1000 mg iv . Post operatively, depending upon P/F ratios, 

A total of 23 bilateral LTx in such phenotype were performed between May 2020 and Aug 2021.

All of them were transferred from tertiary care hospitals across India to our Transplant Hospital.

All of them were ET (Endotracheal) RT PCR negative for SARS-CoV-2 infection for 2 samples taken at least 24-48 hrs apart pre-operatively. The median age of patients in this study was 42 years, with 3 (13%) people aged 60 years or above (Table 1 ). There were 20 (87%) men. Number of subjects with Normal BMI, overweight and obese were 5 (21.7%), 13 (56.5%) and 5 (21.7%) among study population. Out of 23 recipients, 8 (34.7%) recipients had B positive blood group , 5 (21.7%) recipients had A positive blood group, 9 (39.1%) recipients had O positive blood group and 1(4.3%) recipient had AB positive blood group. All 23 recipients received Remdesivir , Steroids , Anticoagulation as part of COVID treatment. Among the study population, Hypertension was the most common morbidity among 7 (30.4%), followed by Diabetes among 3 (13%) and coronary artery disease among 2 (8.7%) participants. The mean ventilation and ECMO days were 48.87 ± 23.43 and 43.78 ± 24.25 respectively. (Table 2) Out of 23 recipients, 22 patients were supported with venovenous (VV) ECMO ( conventional dual cannulae fem-ijv). All 22 patients were awake while on ECMO. One patient had end stage lung disease post COVID leading to respiratory failure requiring High Flow Nasal Cannula ( HFNC) with 40 lit flow.

The mean ischemia time on right and left side was 356 ± 78.58 and 232.35 ± 81.23 minutes respectively. All recipients required multiple blood products transfusions.Intra operatively median number of blood products used were [11 (10, 13) ]. Median number of cryo, FFP, LDPRBC and RDP were [2 (1, 2)], [4 (2, 4) ], [3 (2, 4) ] and [3.5 (2, 4)] respectively. (Table 2 )

At 72 hours post-transplant, 4 (17.4%) participants each had PGD grade 0 and grade 1, 7 (30.4%) had grade 2 and 8 (34.8%) had grade 3 PGD (Table 3 ). The mean duration of ICU stay was 15.83 ± 6.61 days and mean hospital stay was 62.74 ± 32.42 days. Post -Transplantation morbidity included AKI requiring RRT in 6 (26%) recipient , CIN/Neuro-muscular weakness in 13 (56.5%) recipients and Airway Anastomotic stenosis requiring Balloon dilatation in 8 (34%) recipients with SEMS covered stenting done subsequently in 5 (21%) recipients (Fig no. 2). 5 (21%) recipients were discharged with Tracheostomy while rest were successfully decannulated in wards. All recipients were mobilising well at time of discharge.

Pathological Correlation : a) Gross : Fig 4 a (3, 9) months. Out of 23, 15 (65.22%) participants were alive and 8 (34.78%) participants were dead. Among 8 patients who expired, the cause of death was sepsis for 6 patients (75.0%), neurological CVA for 1 patient (12.5%) and CMV for 1 patient (12.5%) ( Table 3) The mean survival time for the patients was 34.540 weeks. The median survival time for the patients was 20 weeks i.e. 50% of the survival was achieved in 20 weeks. (Fig 3) 

Mortality was higher among the people aged 60 and above as compared to people aged below 60 (66.67% Vs 30%, p=0.27). Also people with presence of any co-morbidity had higher proportion of mortality (50% Vs 26.67%, p=0.37). Also people with pre-operative ECMO days of 6 weeks or more had higher mortality (45.5% Vs 25%, p=0.30). Even among people with preoperative ECMO of more than 6 weeks 54.5% of people survived. Median number preoperative ventilation days, ECMO days, number of intra-operative blood products were higher among people with mortality. All the deaths were reported in PGD grade 2 & 3 category with no deaths among PGD 0 & 1 category. Post-operative median hospital days were lower in mortality group, suggesting intra-hospital mortality. (Table 4 

We performed 23 bilateral LTx in recipients affected with Post-Covid fibrotic progressive End Stage Lung Disease. We treated the patients who underwent LTx for COVID-19 with a typical three-drug immunosuppression regimen including calcineurin inhibitors, an anti-metabolite, and steroids. They were also administered solumedrol as well as basiliximab before reperfusion as part of our induction immunosuppression protocol for all lung transplant patients. In addition, they received antimicrobial drugs directed toward the pathogens isolated from the native lungs before transplantation. All recipients underwent serial Bronchoscopies to monitor anastomotic healing, to collect Broncho-alveolar lavages (BALs) to monitor/rule out infections and for toileting. There was no recurrence of SARS-Cov-2 infection in allografts.

We faced certain challenges pre-operatively as well as post-operatively. They concluded that some patients with severe COVID-19 develop an irreversible fibrotic lung disease for which transplantation is likely their only option for survival.

We would like to raise similar concerns of these patients developing multiple nosocomial complications, neuromuscular deconditioning, and malnutrition due to their complicated medical course, which may be an impediment to transplantation in patient. We found these factors impacting post-operative recovery period for select few recipients specifically with age above 60 years , BMI more than 30 , donor-recipient lung size mismatch leading to anatomical volume reduction in some, prolonged ischemia times, AKI postoperatively, etc. More studies are required analysing above risk factors in these post-covid phenotypes going for LTx.

Barbaro et al 10 in their study has re-inforced above findings regarding risk factors. Novel findings in this study include determination of independent associations between mortality and risk factors for ECMO-supported patients with COVID-19. Identified risk factors were age, immunocompromised state, chronic respiratory disease, pre-ECMO cardiac arrest, degree of hypoxaemia, presence of acute kidney injury, and use of ECMO for temporary circulatory support (venoarterial ECMO support vs venovenous ECMO support).

Cypel and Keshavjee 7, have highlighted determinants of LTx . The challenges in selection of candidates for Lung Transplantation in such phenotype also has been highlighted by Domjan et al. 11 Extrapolating above recommendations in post-covid phenotypes would require some deviations.

We propose that candidacy for LTx in such phenotype should be decided by following factors also apart above mentioned : clothing, an intra-procedure rotation plan is necessary to guarantee optimal performance during surgery.

Understanding above key factors is crucial for successful outcomes post LTx in such phenotypes. We propose additional points :

1. Induction Immunosuppression should be for all such recipients as they have higher risk of sensitisation pre-operatively specifically on ECMO support due to need of multiple 

COVID-19) Dashboard [Internet]. Geneva: World Health Organisation

Available from

COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection

COVID-19 pathophysiology: A review

Clinical characteristics of coronavirus disease 2019 in China. 2020

Hospital Mortality and Resource Implications of Hospitalisation with COVID-19 in London, UK: A Prospective Cohort Study

Respiratory follow-up of patients with COVID-19 pneumonia

When to consider lung transplantation for COVID-19

Lung transplantation for COVID-19-associated acute respiratory distress syndrome in a PCR-positive patient

Lung transplantation for patients with severe COVID-19

Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry

Lung Transplantation for End-Stage Respiratory Failure After Severe COVID-19: A Report of 2 Cases

A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression

Novel insight from the first lung transplant of a COVID-19 patient

Histopathologic Findings in the Explant Lungs of a Patient With COVID-19 Treated With Bilateral Orthotopic Lung Transplant

Lung transplantation as therapeutic option in acute respiratory distress syndrome for coronavirus disease 2019-related pulmonary fibrosis

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Brazilian initial experience with lung transplantation due to irreversible lung f ibrosis post-COVID-19 in a national reference center: a cohort study

Lung Transplantation for Patients With COVID-19

Tables and figures : Table 1: Baseline demographic and clinical characteristics of study population (N=23) Baseline parameters Summary